Abstract
BACKGROUND: Alpha-protein kinase 3 (ALPK3) was recently identified as a candidate gene associated with hypertrophic cardiomyopathy (HCM). However, clinical data regarding carriers of ALPK3 variants are limited. Therefore, this study amied to evaluate the prevalence of heterozygous ALPK3 variants in adult patients with HCM and to elucidate the phenotypes of individuals harboring these variants. METHODS: 575 consecutive patients diagnosed with HCM who underwent 3T cardiovascular magnetic resonance (CMR) imaging and whole-exome sequencing genetic testing were recruited. Patients harboring ALPK3 rare missense variants (minor allele frequency < 0.0005) or truncating variants were considered genotype-positive. RESULTS: Among the 575 included patients (65.0% [374/575] male; median age: 50 [40-61] years), 37 (6.43%) showed heterozygous ALPK3 variants. In comparison with sarcomere variant carriers, ALPK3 heterozygotes showed a higher prevalence of apical hypertrophy (59.5% [22/37] vs 20.2% [66/326], P < 0.001) and a lower fibrosis burden, with a two-fold reduction in the incidence of extensive fibrosis (≥15% left ventricle [LV] mass: 8.1% [3/37] vs 14.7% [48/326], P < 0.001). Patients with single ALPK3 variants were more likely to present with apical HCM (ApHCM; 80.0% [16/20]vs 35.3% [6/17], P, 0.006) and show a lower extent of late gadolinium enhancement (LGE; 1.26 [0.00-5.77] % vs 6.00 [3.63-8.50] %, P, 0.011) than those with both ALPK3 and sarcomere variants. CMR characteristics showed no significant differences between carriers with truncating and missense ALPK3 variants. Moreover, among patients with ApHCM, those with single ALPK3 variants were more likely to present with mixed ApHCM (87.5% [14/16] vs 55.2% [16/29] vs 14.3% [1/7], P < 0.05), a lower extent of LGE (0.67 [0-5.77] % vs 6.32 [2.39-10.90] % vs 3.32 [0.00-4.68] %, P < 0.05), and greater free-wall and apex LGE involvement (85.7% [6/7] vs 41.6% [10/24] vs 50% [2/4]) than those with myosin-binding protein C or β-myosin heavy chain variants. CONCLUSION: The clinical phenotype of individuals harboring heterozygous ALPK3 variants showed distinct characteristics, characterized by apical hypertrophy, especially mixed apical hypertrophy, and a lower extent of fibrosis.